Skip to main content

Elicio Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 11, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 11, 2026

ELTX$1.61-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets (unaudited)

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

March 31,2026December 31,2025
Assets
Current assets
Cash and cash equivalents$14,948$18,563
Prepaid expenses and other current assets1,252748
Total current assets16,20019,311
Property and equipment, net249295
Operating lease, right-of-use assets4,5394,782
Restricted cash, noncurrent706704
Other long-term prepaid assets995770
Total assets$22,689$25,862
Liabilities and stockholders’ (deficit) equity
Current liabilities
Accounts payable$272$672
Accrued expenses5,9156,427
Operating lease liability, current1,0421,011
Total current liabilities7,2298,110
Warrant liabilities3,5992,615
Operating lease liability, noncurrent3,8234,094
Long-term debt, net9,4759,407
Total liabilities24,12624,226
Stockholders' (deficit) equity:
Common stock, $0.01 par value per share; 300,000,000 shares authorized; 18,654,350 shares and 17,814,762 shares issued at March 31, 2026 and December 31, 2025, respectively; 18,639,895 and 17,800,307 outstanding as of March 31, 2026 and December 31, 2025, respectively186178
Treasury stock, at cost, 14,455 shares outstanding(150)(150)
Additional paid-in capital244,144235,407
Accumulated other comprehensive loss(122)(127)
Accumulated deficit(245,495)(233,672)
Total stockholders' (deficit) equity(1,437)1,636
Total liabilities and stockholders'(deficit) equity$22,689$25,862
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.